# Cytokinetics (CYTK) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/CYTK
## Company Profile
- Ticker: CYTK
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 61.62 USD
- Market cap: 9627492749.63 USD
- Last updated: 2026-10-13
## Business Overview
### Muscle Biology Specialization
Cytokinetics develops and commercializes medicines that modulate muscle function. Its portfolio is centered on cardiac muscle biology and diseases in which altered contractility contributes directly to symptoms and clinical outcomes.
### MYQORZO in Obstructive HCM
MYQORZO, or aficamten, is a cardiac myosin inhibitor approved in the United States and European Union for adults with symptomatic obstructive hypertrophic cardiomyopathy. The product launched in the United States in January 2026 and forms the company’s emerging commercial franchise.
### Aficamten Lifecycle Development
Cytokinetics is seeking to broaden aficamten across hypertrophic cardiomyopathy. The Phase 3 ACACIA-HCM trial met its dual primary endpoints in symptomatic non-obstructive HCM, while MAPLE-HCM supports a supplemental application in obstructive disease and additional studies address Japanese patients.
### Heart-Failure Pipeline
Omecamtiv mecarbil is a cardiac myosin activator in the confirmatory Phase 3 COMET-HF trial for symptomatic heart failure with severely reduced ejection fraction. This program extends the company’s muscle-directed approach beyond HCM.
## Why The Stock Is Moving

As of Oct 13, 2026, CYTK closed down 1.86% at $61.62. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initial European launch of MYQORZO in Germany expected in the second quarter of 2026.
- FDA action on the aficamten supplemental NDA supported by MAPLE-HCM expected by November 14, 2026.
- Full results from the Phase 3 ACACIA-HCM trial to be presented at a medical congress.

## Recent News
- 2026-10-02 11:30 EST — [Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026](https://biopharmsignal.com/news/CYTK/cytokinetics-announces-four-upcoming-presentations-at-the-hfsa-annual-scientific-a58dfa3b) — Source: Cytokinetics
- 2026-09-30 11:30 EST — [Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy](https://biopharmsignal.com/news/CYTK/cytokinetics-launches-aspen-hcm-a-real-world-study-evaluating-myqorzo-aficamten--cfa81aa4) — Source: Cytokinetics
- 2026-09-17 20:00 EST — [Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-3b441674) — Source: Cytokinetics
- 2026-09-14 11:30 EST — [Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program](https://biopharmsignal.com/news/CYTK/cytokinetics-announces-call-for-proposals-for-ninth-annual-communications-grant--37a5b75d) — Source: Cytokinetics
- 2026-09-02 20:00 EST — [Cytokinetics to Participate in September Investor Conferences](https://biopharmsignal.com/news/CYTK/cytokinetics-to-participate-in-september-investor-conferences-ac3ab76c) — Source: Cytokinetics